Diffusion Pharmaceuticals (DFFN) Short Interest Ratio & Short Volume

Short interest is the volume of Diffusion Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 2,500 shares of DFFN short. 0.12% of Diffusion Pharmaceuticals' shares are currently sold short. Learn More on Diffusion Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.12% of Diffusion Pharmaceuticals' floating shares are currently sold short.

Diffusion Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,500 shares, a decline of 45.7% from the previous total of 4,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Diffusion Pharmaceuticals currently has issued a total of 2,040,000 shares. Some of Diffusion Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Diffusion Pharmaceuticals currently has a public float of 2,040,000 shares.

0.12% of Diffusion Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Diffusion Pharmaceuticals: Aeterna Zentaris Inc. (0.35%), NuCana plc (0.50%), Molecular Templates, Inc. (6.97%), Virios Therapeutics, Inc. (1.11%), Akari Therapeutics, Plc (0.01%), Cyclerion Therapeutics, Inc. (1.03%), Hepion Pharmaceuticals, Inc. (1.19%), Alterity Therapeutics Limited (1.09%), Elevai Labs, Inc. (0.32%), Lixte Biotechnology Holdings, Inc. (4.59%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.34 billion), Occidental Petroleum Co. ($2.88 billion), Coinbase Global, Inc. ($2.50 billion), Rivian Automotive, Inc. ($2.47 billion), Palantir Technologies Inc. ($2.37 billion), Royal Caribbean Cruises Ltd. ($2.33 billion), T. Rowe Price Group, Inc. ($2.29 billion), Tractor Supply ($1.59 billion), Upstart Holdings, Inc. ($1.58 billion), and Enphase Energy, Inc. ($1.52 billion). View all of the most shorted stocks.

Short selling DFFN is an investing strategy that aims to generate trading profit from Diffusion Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Diffusion Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DFFN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DFFN, twice per month. The most recent reporting period available is July, 31 2023.